The current systematic review and meta-analysis aimed at exploring acute effects of intravenous (IV) ketamine, an antagonist of N-methyl-D-aspartate (NMDA), in subjects with current suicidal ideation. We included clinical trials testing a single IV dose of ketamine and assessing changes in suicidal ideation within 4 h after treatment. Meta-analyses based on random-effects models, were carried out generating pooled standardized mean differences (SMDs) between endpoint and baseline scores. Heterogeneity among studies was estimated using the I2 index. We searched main Electronic Databases, identifying five studies that met our inclusion criteria. The trials included 99 subjects treated with IV ketamine bolus or infusion. Data showed a large (SMD = −0.92; 95%CI: −1.40 to −0.44; p < 0.001) and consistent (I2 = 21.6%) decrease of suicidal ideation, with effects comparable between IV bolus and infusion ketamine. Additional analyses confirmed the efficacy of ketamine across different time points. However, relevant, emerging evidence should be considered as ‘very low’ so far. Randomized, controlled and adequately powered trials are needed.

Bartoli, F., Riboldi, I., Crocamo, C., Di Brita, C., Clerici, M., Carrà, G. (2017). Ketamine as a rapid-acting agent for suicidal ideation: A meta-analysis. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 77, 232-236 [10.1016/j.neubiorev.2017.03.010].

Ketamine as a rapid-acting agent for suicidal ideation: A meta-analysis

Bartoli, F
;
Riboldi, I;Crocamo, C;Di Brita, C;Clerici, M;Carrà, G
2017

Abstract

The current systematic review and meta-analysis aimed at exploring acute effects of intravenous (IV) ketamine, an antagonist of N-methyl-D-aspartate (NMDA), in subjects with current suicidal ideation. We included clinical trials testing a single IV dose of ketamine and assessing changes in suicidal ideation within 4 h after treatment. Meta-analyses based on random-effects models, were carried out generating pooled standardized mean differences (SMDs) between endpoint and baseline scores. Heterogeneity among studies was estimated using the I2 index. We searched main Electronic Databases, identifying five studies that met our inclusion criteria. The trials included 99 subjects treated with IV ketamine bolus or infusion. Data showed a large (SMD = −0.92; 95%CI: −1.40 to −0.44; p < 0.001) and consistent (I2 = 21.6%) decrease of suicidal ideation, with effects comparable between IV bolus and infusion ketamine. Additional analyses confirmed the efficacy of ketamine across different time points. However, relevant, emerging evidence should be considered as ‘very low’ so far. Randomized, controlled and adequately powered trials are needed.
Articolo in rivista - Articolo scientifico
Ketamine; Meta-analysis; Suicidal ideation;
ketamine; suicidal ideation; meta-analysis
English
232
236
5
Bartoli, F., Riboldi, I., Crocamo, C., Di Brita, C., Clerici, M., Carrà, G. (2017). Ketamine as a rapid-acting agent for suicidal ideation: A meta-analysis. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 77, 232-236 [10.1016/j.neubiorev.2017.03.010].
File in questo prodotto:
File Dimensione Formato  
10281_149151 Carrà 1-s2.0-S0149763416308430-main.pdf

Solo gestori archivio

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 836.87 kB
Formato Adobe PDF
836.87 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/149151
Citazioni
  • Scopus 71
  • ???jsp.display-item.citation.isi??? 59
Social impact